drugset
drugset / Trial / NCT03163550

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789

NCT03163550 ↗

Phase 1 Completed 40 enrolled Achaogen, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase 1 clinical study is a double-blind, randomized, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics (PK), food effect, and drug interaction potential of ACHN-383 and ACHN-789 co-administered orally as separate capsules in healthy subjects

Timeline

Start
2017-05-17
Primary completion
2017-10-15
Completion
2017-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ACHN-789 Unknown — Oral
Subject Ceftibuten Small molecule — Oral

Indications

No indication recorded.